A image-guided breast biopsy after neoadjuvant chemotherapy (ANC) can be used to evaluate the presence of residual cancer.
This is clear from a study carried out by researchers from the Royal Marsden National Health Service Hospital Consortium, London, University of Texas MD Anderson Cancer Center, and Seoul National University Hospital.
Precisely, the study evaluated the accuracy of post-QNA image-guided biopsy to predict residual cancer in the breast. Of the 166 women involved, 143 underwent vacuum-assisted, image-guided biopsy (AVB) and 23 underwent central cut biopsies.
The ultrasound guide was used in 77.7% of patients and stereotaxic guide was used in 22.3% remaining of patients.
Post-neoadjuvant chemotherapy image-guided biopsy can identify a complete pathologic response in the breast
The results showed that In the 159 patients who underwent a representative image-guided biopsy, the false negative rate was 18.7%.
However, a False negative rate less than 5% in a subgroup analysis of 76 patients with a complete or partial response to clinical treatment, and a residual anomaly in the image of two centimeters or less, and with at least six samples of AVB.
As the investigators have concluded, post-neoadjuvant chemotherapy image-guided biopsy can identify a complete pathologic response in the breast in selected patients. Furthermore, they have underlined that the technique can facilitate risk adaptation surgery and potentially can even identify those who respond to exceptional treatment for de-escalation of local therapy.
Adjuvant therapy includes any treatment given after primary therapy (such as surgery) to increase the chances of long-term survival; the Neoadjuvant therapy is the treatment given before the primary therapy.
Because we all need health … ConSalud.es
–
